文献速递肾小球疾病

泰它西普对IgA肾病循环Gd-IgA1及含IgA免疫复合物的影响

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2024-01-10

该2期临床试验纳入24例IgA肾病患者,随机分为安慰剂组、泰它西普160 mg组和240 mg组,检测基线及第4、12、24周血浆Gd-IgA1、含IgA免疫复合物及补体片段水平,分析其与蛋白尿下降的关联。结果显示泰它西普显著降低Gd-IgA1及IgG-IgA和poly-IgA免疫复合物,且免疫复合物下降与蛋白尿减少相关,呈剂量依赖性;补体C3a、C5a、sC5b-9无显著变化。

要点

  • 泰它西普160 mg和240 mg治疗24周显著降低循环Gd-IgA1及含IgA免疫复合物。
  • 血浆Gd-IgA1和IgG-IgA或poly-IgA免疫复合物下降与蛋白尿减少相关。
  • IgG-IgA或poly-IgA免疫复合物呈剂量依赖性变化,与蛋白尿下降一致。

核心结论

  • 泰它西普降低循环Gd-IgA1和含IgA免疫复合物,其中IgA免疫复合物水平与蛋白尿下降更一致。

研究设计与样本

  • 2期临床试验中24例受试者的血浆样本,基线及第4、12、24周采集,安慰剂组8例、160 mg组9例、240 mg组7例。

主要发现

  • 160 mg组24周后Gd-IgA1下降43.9%(95%CI 29.8%, 55.1%),IgG-IgA免疫复合物下降31.7%(14.4%, 45.5%),poly-IgA免疫复合物下降41.3%(6.5%, 63.1%)。
  • 240 mg组24周后Gd-IgA1下降50.4%(38.6%, 59.9%),IgG-IgA免疫复合物下降42.7%(29.5%, 53.4%),poly-IgA免疫复合物下降67.2%(48.5%, 79.1%)。
  • 泰它西普治疗期间循环C3a、C5a、sC5b-9水平无显著变化。
  • 血浆Gd-IgA1和IgG-IgA或poly-IgA免疫复合物下降均与蛋白尿减少相关。

临床怎么用

  • 泰它西普治疗IgA肾病时,可监测循环Gd-IgA1及含IgA免疫复合物以评估生物学反应。
  • IgG-IgA或poly-IgA免疫复合物下降呈剂量依赖性,与蛋白尿减少一致,可作为潜在疗效标志物。

局限性

  • 样本量小(共24例),各组例数少(8、9、7例)。
  • 仅为2期临床试验的血浆标志物分析,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Telitacicept, a transmembrane activator and cyclophilin ligand interactor (TACI) fusion protein targeting B cell activating factor and a proliferation-inducing ligand (APRIL), has proven efficacy in treating Immunoglobulin A (IgA) nephropathy (IgAN). However, serum biomarkers that could predict the clinical response during the treatment remain unclear. METHODS: Plasma samples from 24 participants in the phase 2 clinical trial were collected at baseline and after 4, 12, and 24 weeks; with 8 participants in the placebo group, 9 in the 160 mg group, and 7 in the 240 mg group. We measured the levels of galactose-deficient-IgA1 (Gd-IgA1), IgA-containing immune complexes, C3a, C5a, and sC5b-9. The association between the changes in these markers and proteinuria reduction was analyzed. RESULTS: After 24 weeks of treatment, Gd-IgA1 decreased by 43.9% (95% confidence interval: 29.8%, 55.1%), IgG-IgA immune complex by 31.7% (14.4%, 45.5%), and poly-IgA immune complex by 41.3% (6.5%, 63.1%) in the 160 mg group; Gd-IgA1 decreased by 50.4% (38.6%, 59.9%), IgG-IgA immune complex decreased by 42.7% (29.5%, 53.4%), and poly-IgA immune complex decreased by 67.2% (48.5%,79.1%) in the 240 mg group. There were no significant changes in the circulatory C3a, C5a, or sC5b-9 levels during telitacicept treatment. Decreases in both plasma Gd-IgA1 and IgG-IgA or poly-IgA immune complexes were associated with proteinuria reduction. In turn, IgG-IgA or poly-IgA immune complexes showed a dose-dependent effect, consistent with proteinuria reduction during telitacicept treatment. CONCLUSION: Telitacicept lowered both circulating Gd-IgA1 and IgA-containing immune complexes, whereas IgA immune complex levels were more consistent with decreased proteinuria.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Zan J, Liu L, Li G, et al. Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy. Kidney Int Rep. 2024. PMID: 38765591. doi:10.1016/j.ekir.2024.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。